Great Point Partners has significantly expanded its investment in Apogee Therapeutics, increasing its stake by 70,000 shares to a total holding of 374,000 shares valued at $28.23 million. The position now represents the fund's largest individual holding, comprising 9.15% of its total assets under management.
Apogee Therapeutics shares have appreciated 100% over the past 12 months, reflecting investor interest in the biopharmaceutical company's pipeline. The company is developing monoclonal antibody therapies targeting inflammatory diseases, with clinical development focused on atopic dermatitis treatment.
The company is expected to release Phase 2 clinical data for its atopic dermatitis candidate in the first half of 2026, a milestone that could significantly influence the stock's trajectory. Great Point Partners' increased conviction in the investment, evidenced by the substantial position buildup, suggests confidence in the company's clinical and commercial prospects.